Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Molecular Mechanism of c-Myc Nuclear Output Mediated By m5C Binding Protein Alyref in c-Myc+ DLBCL

Lili Zhou, Yi Luo, Li Yu

Blood (2024) 144 (Supplement 1): 5755.

https://doi.org/10.1182/blood-2024-206558

Published: 2024

Journal Articles

The Molecular Mechanism of CD36 in Regulating Cholesterol Metabolism Reprogramming to Drive the Pathogenesis of Diffuse Large B-Cell Lymphoma Cells

Wei Cheng, Lili Zhou, Qingqing Luo, Yi Luo, Li Yu

Blood (2024) 144 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2024-206523

Published: 2024

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Yan Lu, Shaoguang Li, Aibin Liang

Blood (2024) 144 (Supplement 1): 6524.

https://doi.org/10.1182/blood-2024-208414

Published: 2024

Journal Articles

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Ping Li, Jian Ge, Shiguang Ye, Lili Zhou, Yiming Gong, Huaying Ruan, Hosein Kouros-Mehr, Aibin Liang

Blood (2024) 144 (Supplement 1): 3475.

https://doi.org/10.1182/blood-2024-199236

Published: 2024

Journal Articles

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

Bin Xue, Xiu Luo, Yifan Liu, Lili Zhou, Shiguang Ye, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2023-184885

Published: 2023

Journal Articles

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Blood (2023) 142 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2023-182817

Published: 2023

Journal Articles

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Lili Zhou, Shiguang Ye, Xiuyong Dang, Shaoguang Li, Ping Li

Blood (2023) 142 (Supplement 1): 6276.

https://doi.org/10.1182/blood-2023-186563

Published: 2023

Journal Articles

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

Fangce WANG, Bing Li, Ping Li, Shiguang Ye, Lili Zhou, Wenjun Zhang, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2023-185161

Published: 2023

Journal Articles

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Shiguang Ye, Lili Zhou, Yan Lu, Xiu Luo, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2023-184765

Published: 2023

Journal Articles

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

Yan Lu, Shiguang Ye, Lili Zhou, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6925.

https://doi.org/10.1182/blood-2023-182763

Published: 2023

Journal Articles

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lili Zhou, Shiguang Ye, Ping Li, Bing Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6258.

https://doi.org/10.1182/blood-2023-180524

Published: 2023

Journal Articles

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

Ping Li, Wei Liu, Shiguang Ye, Lili Zhou, Judy Zhu, Jiaqi Huang, Jing Li, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Xin Yao, Hui Wan, Yihong Yao, Aibin Liang, Dehui Zou

Blood (2023) 142 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2023-181527

Published: 2023

Journal Articles

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Bin Xue, Xiu Luo, Yifan Liu, Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2023-180500

Published: 2023

Journal Articles

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

Lili Zhou, Yifan Liu, Shiguang Ye, Ping Li, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 3137.

https://doi.org/10.1182/blood-2023-184352

Published: 2023

Journal Articles

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Haiyan Jiang, Ping Li, Lili Zhou, Shiguang Ye, Xiu Luo, Yan Lu, Bin Xue, Shaoguang Li, Aibin Liang

Blood (2023) 142 (Supplement 1): 6934.

https://doi.org/10.1182/blood-2023-188386

Published: 2023

Journal Articles

Development of Hypertension and Atrial Fibrillation Following Diagnosis of B-Cell Malignancies - a Retrospective Analysis of US Marketscan Insurance Claims Database

Lili Zhou, Binglin Yue, Soraya Azmi, Meng Zhang, Aileen Cleary Cohen

Blood (2022) 140 (Supplement 1): 12377–12378.

https://doi.org/10.1182/blood-2022-167596

Published: 2022

Journal Articles

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-137826

Published: 2020

Journal Articles

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138538

Published: 2020

Journal Articles

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 2818.

https://doi.org/10.1182/blood-2019-129666

Published: 2019

Journal Articles

Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T Cells

Lili Zhou, Liang Aibin, MD, Shaoguang Li, Shiguang Ye, Ping Li

Blood (2019) 134 (Supplement_1): 5315.

https://doi.org/10.1182/blood-2019-130566

Published: 2019

NARROW

Molecular Mechanism of c-Myc Nuclear Output Mediated By m5C Binding Protein Alyref in c-Myc+ DLBCL

The Molecular Mechanism of CD36 in Regulating Cholesterol Metabolism Reprogramming to Drive the Pathogenesis of Diffuse Large B-Cell Lymphoma Cells

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma with MYC +

Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR T-a Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies

Development and Validation of a Clinical Prediction Model for the Efficacy of CD19 CAR T-Cell Therapy in DLBCL

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Characterization of Hemophagocytic Lymphohistio(HLH）in Relapsed Diffuse Large B-Cell Lymphoma Patients after CAR-T Therapy

Clinical Characteristics of Long-Term Survivors Treated with BCMA CAR T Cell

The Efficacy and Safety of Decitabine Combined with Fludarabine and Cyclophosphamide As Conditioning Regimen in Second CD19 CAR-T Infusion

Zanubrutinib Combined Regimen As Bridging Treatment on Promising Clinical Outcome of CD19 Chimeric Antigen Receptor T-Cell Therapies in Relapsed or Refractory Large B-Cell Lymphoma

BTK Inhibitors and Chidamide-Combined Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy

CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations

Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma（R/R DLBCL）

To Investigate the Efficacy of Long-Term Step-Reduction Methylprednisolone in the Treatment of Severe Persistent Thrombocytopenia after CAR-T Cell Therapy

Development of Hypertension and Atrial Fibrillation Following Diagnosis of B-Cell Malignancies - a Retrospective Analysis of US Marketscan Insurance Claims Database

Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL

Early Clinical Results of a Novel Anti-CD20 Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL Patients Who Are Relapsed/Resistant Following CD19 CAR-T Therapy

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Patients with Bone and Bone Marrow Involvement Had Better OS and PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only